{"CVE Code": "CVE-2015-3965", "Description": "Hospira Symbiq Infusion System 3.13 and earlier allows remote authenticated users to trigger \"unanticipated operations\" by leveraging \"elevated privileges\" for an unspecified call to an incorrectly exposed function.", "NVD Link": "https://nvd.nist.gov/vuln/detail/CVE-2015-3965", "Vulnerability Categories": "N/A", "Affected Products": "\nPfizer\u00bbSymbiq Infusion System FirmwareVersions  up to, including, (<=) 3.13cpe:2.3:o:pfizer:symbiq_infusion_system_firmware:*:*:*:*:*:*:*:*Matching versionsWhen used together with:Pfizer\u00bbSymbiq Infusion System\u00bbVersion:N/A", "EPSS Score": "0.26% Probability of exploitation activity in the next 30 days\n~ 65 % Percentile, the proportion of vulnerabilities that are scored at or less", "EPSS History": "\n #  Date  Old EPSS Score  New EPSS Score  Delta (New - Old) \n 1  2024-12-17  0.21%  0.26%  +0.06 \n 2  2023-03-07  1.06%  0.21%  -0.85 ", "CVSS Scores": "9.0", "CWE": [{"CWE_ID": "CWE-264", "CWE_link": "/cwe-details/264/cwe.html"}], "Reference": [{"ref_link": "https://ics-cert.us-cert.gov/advisories/ICSA-15-174-01", "ref_desc": "Hospira Symbiq Infusion System Vulnerability | CISAUS Government Resource;Third Party Advisory", "ref_cve_link": "N/A"}]}